Ernst & Young Report:

Danish Biotech Pipeline Third in Europe

2012.08.03

A new report by Ernst & Young benchmarks Denmark third in Europe when it comes to drug development. Actually, with a Danish population of only 5 million inhabitants, the number of drugs in development per capita largely exceeds all other European markets.

England and Germany, which are respectively no.1 and 2 on the list of drug candidates in preclinical and clinical development, have 6-8 times larger populations than Denmark, this means that if the figures were made up per capita, Denmark would rank no.1 way ahead of even Germany and England.

-“One of the reasons why Denmark’s pipeline of drug development is so strong is the high number of innovative biotech companies. Denmark has more than 160 Biotech firms which is about equivalent to a country like France with a ten times larger population.”

-“Even though many of the Danish biotech companies are relatively small, it is important to have a critical mass of research companies in the sector in order to get drugs into clinical development. Furthermore it is crucial that the strong position in drug development is backed by a proven ability to take drug candidates into preclinical and clinical development and further to the marked.”

Denmark is one of the best places in the world to execute high-quality clinical trials

The impressive pipeline of drugs in development is linked to the great conditions for conducting clinical trials in Denmark. Applying for a clinical trials authorisation in Denmark is simpler and faster than anywhere else in Europe and a large number of CROs are active in Denmark, conducting clinical trials at all stages.

Denmark has a long tradition for patient and population registration, including a unique social security number for each citizen and as the Danish population is quite homogeneous and relatively non-mobile, the country is ideal for longitudinal studies. Danish hospitals have a broad experience and are very efficient in executing clinical trials.

A generally high educational level and good English skills is another element that benefits the process and quality of doing clinical trials in Denmark.

Next step

Clinical Trials

in Denmark

The multinational pharmaceutical company GSK has been present in Denmark for more than 40 years. Watch V.P. Mike Connell explain why.

"Medicon Valley is one of the top 3 biotech clusters in the world. Danish scientists deliver some of the best quality research in the world. In the last 8 years GSK has invested more than 15 billion Danish kroner in Danish biotech companies."

About Cookies

Information about cookies

A cookie is a small text file, which is placed on your computer or other devices.
It makes it possible for us to recognize your computer and gather information about
which pages and functions are visited with your computer. Cookies contain only anonymous
information.

Cookies are used by most websites and are in many cases essential for the website
to work properly.

Cookies on this website

We use cookies on this website for various purposes related to functionality, web
analysis and marketing. We use cookies primarily to gather statistics about the
users’ visits. The information gathered is used to improve the user experience on
our website.

You can read more about the cookies we use under the three tabs. The cookies are
divided into categories and you will find information about their name, expiration,
purpose and company.

No to cookies

If you wish to decline the use of cookies now or in the future, you can change the
permission in your browser settings. You block for the use of cookies from this
and other websites by adding the domain under settings in your browser.

What happens if I say no to cookies?

If you choose to decline cookies in your browser, your device will not be tracked
when you browse the internet. However, please note that by declining cookies you
will automatically also not allow a lot of functionality on various websites and
they may not work correctly.